JNJ-28312141

JNJ-28312141 is a novel orally active small molecule inhibitor targeting the colony-stimulating factor 1 receptor (CSF-1R) and FMS-related receptor tyrosine kinase 3 (FLT3). It was developed for potential use in oncology, specifically for solid tumors, bone metastases, and acute myeloid leukemia. The drug acts by inhibiting CSF-1R kinase activity—thereby reducing tumor-associated macrophages and osteoclast differentiation—and also inhibits FLT3 signaling relevant to certain leukemias. In preclinical models, it demonstrated efficacy in suppressing tumor growth and preventing bone erosion associated with metastatic disease. The compound was initially developed by Johnson & Johnson but its development has been discontinued[1][3][5][6].

Other names

JNJ-28312141 FREE BASEJNJ28312141 FREE BASEJNJ 28312141 FREE BASEJNJ-28312141 hydrochlorideJNJ28312141 hydrochlorideJNJ 28312141 hydrochloride1H-imidazole-2-carboxamide 5-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-(dimethylamino)acetyl]-4-piperidinyl]phenyl4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide